CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Rituxan for Acute Lymphoblastic Leukemia – Details

Project Number PC0102-000
Brand Name Rituxan
Generic Name Rituximab
Strength 200mg and 500mg vials
Tumour Type Leukemia
Indication Acute Lymphoblastic Leukemia
Funding Request In combination with standard of care chemotherapy for Philadelphia chromosome negative, CD20 antigen positive, B-cell precursor acute lymphoblastic leukemia in adults
Review Status Complete
Pre Noc Submission Yes
NOC Date N/A
Manufacturer Hoffmann-La Roche Limited
Sponsor Cancer Care Manitoba
Submission Date February 13, 2017
Submission Deemed Complete February 21, 2017
Submission Type Initial
Prioritization Requested Not Requested
Stakeholder Input Deadline ‡ February 28, 2017
Check-point meeting April 12, 2017
pERC Meeting June 15, 2017
Initial Recommendation Issued June 29, 2017
Feedback Deadline ‡ July 14, 2017
pERC Reconsideration Meeting August 17, 2017
Final Recommendation Issued August 31, 2017
Notification to Implement Issued September 18, 2017
Therapeutic Area Acute Lymphoblastic Leukemia
Recommendation Type Do not reimburse

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.